IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3300 participants.
Also called NCT07875179
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,300 participants
- Registry
-
NCT07875179
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07875179. Randomized; no masking; primary purpose treatment. Start 2026-09-28 (anticipated); primary completion 2028-09-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI
- Acronym
- IMPROVE-STEMI
- Condition
- ST Elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- Recombinant Streptokinase
- Lead sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Collaborator
- China Association for Disaster & Emergency Rescue Medicine
- Collaborator
- Henan Singtier Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07875179- Content hash
0effa2a32aac45e1ff64c8b1e13f1813c52ddfea6d7cf828b803d7130c4988fa